
Prostate Cancer
Latest News

Latest Videos

CME Content
More News

The recent episode of the "Oncology Peer Review On-The-Go" podcast features Alexandra Sokolova, MD, discussing her article on germline testing and NCCN guidelines for patients with prostate cancer.

Research from an observational study suggests it will take time for sexual satisfaction scores to improve among patients with erectile dysfunction due to robot-assisted radical prostatectomy for localized prostate cancer.

Scott Tagawa, MD, spoke about the implications of the results from his research on treatment patterns of patients with metastatic castration-sensitive prostate cancer, as well as the need for further studies with other data sets.

Dr Morgans discusses biomarker testing protocols and signs to look for during testing.

Alicia Morgans, MD, MPH, explains the different testing that should be done when being diagnosed with metastatic prostate cancer.

Although there was no resulting benefit to overall survival with the addition of short-term androgen deprivation to dose-escalated radiotherapy, patients with intermediate-risk prostate cancer experienced other disease benefits with this treatment approach.

BXCL701 and pembrolizumab may resolve the need for FDA-approved therapies for patients with small cell neuroendocrine prostate cancer, according to investigators.

A specialist describes the advances being made in metastatic prostate cancer and provides some clinical pearls for community oncologists.

Oliver Sartor, MD, discusses the use of rucaparib in treating metastatic prostate cancer.

A key opinion leader explains the role of PARP inhibitors in metastatic prostate cancer and reviews clinical trial data.

Dr. Oliver Sartor illustrates the systemic treatment options for metastatic castration-resistant prostate cancer and what to consider when choosing therapies.

Jun Gong, MD, gives his perspective on a review article published in ONCOLOGY about the necessary relationship between medical oncologists and genetic counselors to help treat patients with prostate cancer.

Results of multiple studies have shown that a proportion of men with advanced prostate cancer carry germline DNA damage repair mutations. This article summarizes recommendations for germline testing in prostate cancer and describes care models for providing counseling and testing.

Brian Helfand, MD, PhD, and Steven Finkelstein, MD, FACRO, discussed the phase 2/3 EMPIRE-1 trial focusing on 18F-fluciclovine PET/CT imaging versus conventional imaging to guide postprostatectomy salvage radiotherapy for patients with prostate cancer.

Scott T. Tagawa, MD, MS, on Compelling ESMO Data for Metastatic Castration-Sensitive Prostate Cancer
Scott Tagawa, MD, MS, detailed 2 presentations from ESMO’s presidential symposium that he thinks will have an impact on treating patients with metastatic castration-sensitive prostate cancer.

CancerNetwork® sat down with Alicia Morgans MD, MPH, at the 2021 European Society for Medical Oncology to talk survival and progression outcomes from the CARD trial in patients with metastatic castration-resistant prostate cancer.


















































